Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)‘s stock had its “buy” rating reaffirmed by equities researchers at Cantor Fitzgerald in a research note issued to investors on Thursday. They presently have a $50.00 price objective on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 103.67% from the stock’s current price.
Other research analysts also recently issued reports about the company. BidaskClub upgraded Paratek Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 10th. HC Wainwright increased their price objective on Paratek Pharmaceuticals from $36.00 to $43.00 and gave the stock a “buy” rating in a report on Tuesday, July 18th. Zacks Investment Research upgraded Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price objective for the company in a report on Saturday, August 5th. ValuEngine downgraded Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday. Finally, Raymond James Financial, Inc. reiterated a “strong-buy” rating and set a $36.00 price objective on shares of Paratek Pharmaceuticals in a report on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $37.44.
Shares of Paratek Pharmaceuticals (PRTK) traded down 2.02% during midday trading on Thursday, hitting $24.30. The company had a trading volume of 314,883 shares. The firm’s market capitalization is $674.59 million. Paratek Pharmaceuticals has a 12-month low of $9.80 and a 12-month high of $29.00. The firm’s 50-day moving average is $23.26 and its 200-day moving average is $21.71.
Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.89) by $0.25. The firm had revenue of $7.51 million for the quarter, compared to the consensus estimate of $7.50 million.
WARNING: “Paratek Pharmaceuticals, Inc. (PRTK) Receives Buy Rating from Cantor Fitzgerald” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://sportsperspectives.com/2017/09/22/paratek-pharmaceuticals-inc-prtk-receives-buy-rating-from-cantor-fitzgerald.html.
In other Paratek Pharmaceuticals news, Chairman Michael Bigham sold 5,075 shares of the firm’s stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $23.58, for a total value of $119,668.50. Following the completion of the transaction, the chairman now directly owns 109,500 shares in the company, valued at $2,582,010. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Adam Woodrow sold 3,800 shares of the firm’s stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $23.58, for a total value of $89,604.00. Following the completion of the transaction, the vice president now owns 69,500 shares of the company’s stock, valued at $1,638,810. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,365 shares of company stock valued at $409,467. Corporate insiders own 4.90% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the business. Broadfin Capital LLC grew its stake in Paratek Pharmaceuticals by 23.7% in the second quarter. Broadfin Capital LLC now owns 277,020 shares of the specialty pharmaceutical company’s stock valued at $6,676,000 after purchasing an additional 53,158 shares in the last quarter. California State Teachers Retirement System grew its stake in Paratek Pharmaceuticals by 7.2% in the second quarter. California State Teachers Retirement System now owns 41,722 shares of the specialty pharmaceutical company’s stock valued at $1,006,000 after purchasing an additional 2,800 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Paratek Pharmaceuticals by 21.0% in the second quarter. The Manufacturers Life Insurance Company now owns 18,650 shares of the specialty pharmaceutical company’s stock valued at $449,000 after purchasing an additional 3,233 shares in the last quarter. State Street Corp boosted its stake in shares of Paratek Pharmaceuticals by 112.3% during the 2nd quarter. State Street Corp now owns 616,112 shares of the specialty pharmaceutical company’s stock worth $14,850,000 after acquiring an additional 325,856 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Paratek Pharmaceuticals by 40.9% during the 2nd quarter. Goldman Sachs Group Inc. now owns 131,723 shares of the specialty pharmaceutical company’s stock worth $3,175,000 after acquiring an additional 38,222 shares during the period. Hedge funds and other institutional investors own 82.33% of the company’s stock.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.